Table 1 Cardiovascular outcomes in RCTs evaluating EPA supplementation
From: The multidimensional benefits of eicosapentaenoic acid: from heart health to inflammatory control
Study | Study size | Daily EPA dose | CVS risk profile | Follow-up time (years) | Outcome (HR: 95% CI) |
|---|---|---|---|---|---|
Yokoyama et al. (2007) (JELIS) [32] | 18,645 | 1800 mg | Hypercholesterolemia | 4.6 | HR: 0.81 (0.69–0.95) |
Nosaka et al. (2017) [33] | 241 | 1800 mg | Recent acute coronary syndrome | 1 | HR 0.42, 95% CI 0.21–0.87 |
Bhatt et al. (2019) (REDUCE-IT) [34] | 8179 | 4000 mg | Established ASCVD or diabetes with additional ASCVD risk | 4.9 | HR: 0.75 (0.68–0.83) |